Financial Performance - In 2024, the company achieved operating revenue of 774 million yuan, a year-on-year increase of 12.04% [1] - The net profit attributable to shareholders reached 76.73 million yuan, a significant year-on-year growth of 134.66% [1] - The net profit after deducting non-recurring gains and losses was 51.21 million yuan, up 146.94% year-on-year [1] - Basic earnings per share were 0.18 yuan [1] Profitability Metrics - The gross profit margin for 2024 was 57.27%, an increase of 2.30 percentage points year-on-year [3] - The net profit margin improved to 9.90%, up 5.17 percentage points year-on-year [3] - The weighted average return on net assets was 4.68%, an increase of 2.65 percentage points year-on-year [3] Expense and Cash Flow Analysis - Total period expenses for 2024 amounted to 357 million yuan, a year-on-year increase of 7.03% [3] - Selling expenses were 251 million yuan, up 18.88% year-on-year due to increased academic promotion activities [3] - Research and development expenses decreased by 24.31% to 59.13 million yuan [3] - Net cash flow from operating activities was 162 million yuan, down 26.25% year-on-year [3] - Net cash outflow from investing activities was 107 million yuan, primarily for production base construction and smart transformation [3] Business Segment Performance - Revenue from the pharmaceutical industry was 651 million yuan, a year-on-year increase of 15.39%, accounting for 84.02% of total revenue [3] - Revenue from ear, nose, and throat medications was 265 million yuan, up 28.26% year-on-year [3] - Revenue from digestive system medications reached 178 million yuan, a year-on-year increase of 11.46% [3] - Revenue from psychiatric and neurological medications was 145 million yuan, up 14.06% year-on-year [3] New Business Developments - The company received approval for the special medical food project TY005, with production lines gradually releasing capacity [4] - E-commerce sales exceeded 13 million yuan [4] - The company is advancing four tumor-related Class 1 new drug pipelines, with the HSN003 project entering the IND application preparation stage [4] - A cash dividend of 0.50 yuan per 10 shares (including tax) is proposed for 2024 [4]
华森制药2024年营收7.74亿元 净利润7673.02万元